Product Description
The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aperta Biosciences, LLC
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Guatemala
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Blepharitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06720896 |
VISTA-1 | P2 |
Not yet recruiting |
Blepharitis |
2026-02-01 |
50% |
2025-08-30 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|